RxDoctor Payments Data

Richard Cassidy, MD

Radiation Oncology · Jacksonville, FLNPI 1427391861

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations.

$1,706in general payments, 2019–2025

Across 56 payments — averaging $30.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$327
  • GT Medical Technologies, Inc$229
  • Foundation Medicine, Inc.$196
  • Daiichi Sankyo Inc.$148
  • Pfizer$137
  • Regeneron Healthcare Solutions, Inc.$125
  • plus $544 from 22 others
$82,351in research payments, 2019–2025

Across 7 payments — averaging $11,764 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$82K

What the payments were for

  • Food & beverage$1,706100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,706 in reported general payments places this provider in the 65th percentile of 465 radiation oncology providers in Florida.

See all radiation oncology providers in Florida

Medicare billing

Part B allowed, 2024
$1,851,021
Medicare patients
276
Services billed
7,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lidocaine Hcl ViscousLidocaine Hcl23$537
SsdSilver Sulfadiazine29$377
Ondansetron OdtOndansetron12$358
Sucralfate11$247
Dexamethasone14$225
Methylprednisolone18$149
Memantine Hcl14$127
Pantoprazole Sodium23$90
Sodium ChlorideSodium Chloride Irrig Solution24$82
Lorazepam36$70

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →